NIH Hospital Chief Says New Vaccine Clinic Adds No Cost or Space

Jack Leslie, the chair of the board overseeing the National Institutes of Health Clinical Center Research Hospital, warned that the new vaccine injury clinic could damage the institution's standing. He made the comments during a regularly scheduled board meeting, where he departed from the usual agenda to address the recent opening of the facility.

Leslie criticized the surprise ribbon-cutting ceremony attended by Health Secretary Robert F. Kennedy Jr. The event featured a panel of individuals who described themselves as vaccine injured. These speakers sat behind placards with that label and conversed with Kennedy and other senior Trump administration officials.

The board chair acknowledged that some members might prefer silence regarding the Secretary's activities. Leslie argued that remaining quiet would be a failure of their advisory role. He stated that the board had a duty to speak up despite potential friction.

Leslie clarified that his objection was not to the scientific study of vaccine harms. He noted that serious reactions are rare but real. He added that patients who believe they have been injured should be taken seriously by medical professionals.

Jonathan Green, the hospital's chief executive officer, supported Leslie's account of the clinic's status. Green sat beside Leslie during the meeting and described the new facility as a standard individual protocol. He emphasized that the NIH has researched vaccine safety and efficacy for decades.

Green and Leslie agreed that the new clinic does not bring additional funding or extra physical space to the hospital. The NIH already maintains a center dedicated to studying vaccine injuries. The new clinic functions as a modest addition to existing research efforts.

The remarks highlight a distinction between the high-profile public launch and the clinic's practical operations. Leslie framed the issue as a matter of institutional reputation for a hospital that serves patients with rare conditions. Green presented the clinic as a routine step in ongoing scientific work.

Leslie described the hospital as a house of hope. This nickname reflects its role as a final destination for patients who have exhausted other treatment options. The board's comments suggest a focus on protecting that specific reputation.

Green noted that the research into vaccine safety continues. He positioned the new clinic within the broader context of decades of NIH work. The hospital leadership appears to view the addition as a continuation of established scientific inquiry rather than a new initiative.

Leslie's comments came after the ceremony where Kennedy opened the clinic. The board meeting provided a formal setting for the chair to voice his concerns. The discussion centered on the impact of the clinic's public launch on the hospital's image.

The hospital serves patients with rare conditions. Leslie argued that the board must be mindful of how external events affect this group. The clinic's lack of new funding and space was a central point in both leaders' remarks.

Green and Leslie presented a unified view on the clinic's resources. They indicated that the facility operates within the existing NIH framework. The board's stance reflects a balance between supporting research and protecting institutional standing.